
Michail A. Belyavskyi
Examiner (ID: 4269, Phone: (571)272-0840 , Office: P/1644 )
| Most Active Art Unit | 1644 |
| Art Unit(s) | 1644 |
| Total Applications | 1784 |
| Issued Applications | 857 |
| Pending Applications | 294 |
| Abandoned Applications | 680 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17355376
[patent_doc_number] => 20220016172
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-20
[patent_title] => ACTIVATION OF MARROW INFILTRATING LYMPHOCYTES IN HYPOXIC ALTERNATING WITH NORMOXIC CONDITIONS
[patent_app_type] => utility
[patent_app_number] => 17/490691
[patent_app_country] => US
[patent_app_date] => 2021-09-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6701
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17490691
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/490691 | ACTIVATION OF MARROW INFILTRATING LYMPHOCYTES IN HYPOXIC ALTERNATING WITH NORMOXIC CONDITIONS | Sep 29, 2021 | Abandoned |
Array
(
[id] => 17334592
[patent_doc_number] => 20220000923
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-06
[patent_title] => PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY
[patent_app_type] => utility
[patent_app_number] => 17/480525
[patent_app_country] => US
[patent_app_date] => 2021-09-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 104195
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 316
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17480525
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/480525 | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy | Sep 20, 2021 | Issued |
Array
(
[id] => 18769491
[patent_doc_number] => 20230364261
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-16
[patent_title] => TARGETED ANTIGEN DELIVERY SYSTEM AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/246083
[patent_app_country] => US
[patent_app_date] => 2021-09-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14653
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 72
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18246083
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/246083 | TARGETED ANTIGEN DELIVERY SYSTEM AND USES THEREOF | Sep 20, 2021 | Pending |
Array
(
[id] => 17334594
[patent_doc_number] => 20220000925
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-06
[patent_title] => PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY
[patent_app_type] => utility
[patent_app_number] => 17/480587
[patent_app_country] => US
[patent_app_date] => 2021-09-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 104287
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 305
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17480587
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/480587 | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy | Sep 20, 2021 | Issued |
Array
(
[id] => 17618971
[patent_doc_number] => 11337998
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-05-24
[patent_title] => Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
[patent_app_type] => utility
[patent_app_number] => 17/480596
[patent_app_country] => US
[patent_app_date] => 2021-09-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 138
[patent_figures_cnt] => 196
[patent_no_of_words] => 104320
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 254
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17480596
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/480596 | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy | Sep 20, 2021 | Issued |
Array
(
[id] => 17334593
[patent_doc_number] => 20220000924
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-06
[patent_title] => PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY
[patent_app_type] => utility
[patent_app_number] => 17/480534
[patent_app_country] => US
[patent_app_date] => 2021-09-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 104270
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 296
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17480534
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/480534 | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy | Sep 20, 2021 | Issued |
Array
(
[id] => 17503451
[patent_doc_number] => 20220096553
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-31
[patent_title] => METHODS OR GENERATING T-CELLS FROM STEM CELLS AND IMMUNOTHERAPEUTIC METHODS USING THE T-CELLS
[patent_app_type] => utility
[patent_app_number] => 17/478875
[patent_app_country] => US
[patent_app_date] => 2021-09-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 54481
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17478875
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/478875 | Methods or generating T-cells from stem cells and immunotherapeutic methods using the T-cells | Sep 16, 2021 | Issued |
Array
(
[id] => 18923288
[patent_doc_number] => 20240026292
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-25
[patent_title] => ENGINEERED IMMUNE CELLS FOR REAGENT DELIVERY
[patent_app_type] => utility
[patent_app_number] => 18/044482
[patent_app_country] => US
[patent_app_date] => 2021-09-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14352
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -32
[patent_words_short_claim] => 19
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18044482
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/044482 | ENGINEERED IMMUNE CELLS FOR REAGENT DELIVERY | Sep 8, 2021 | Pending |
Array
(
[id] => 18568299
[patent_doc_number] => 20230258635
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-17
[patent_title] => T CELL PHENOTYPES ASSOCIATED WITH RESPONSE TO ADOPTIVE CELL THERAPY
[patent_app_type] => utility
[patent_app_number] => 18/024430
[patent_app_country] => US
[patent_app_date] => 2021-09-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23833
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18024430
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/024430 | T CELL PHENOTYPES ASSOCIATED WITH RESPONSE TO ADOPTIVE CELL THERAPY | Sep 7, 2021 | Pending |
Array
(
[id] => 20453237
[patent_doc_number] => 12516289
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-01-06
[patent_title] => Methods of producing T memory stem cell populations
[patent_app_type] => utility
[patent_app_number] => 17/465577
[patent_app_country] => US
[patent_app_date] => 2021-09-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 14
[patent_figures_cnt] => 93
[patent_no_of_words] => 8029
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 42
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17465577
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/465577 | Methods of producing T memory stem cell populations | Sep 1, 2021 | Issued |
Array
(
[id] => 18691047
[patent_doc_number] => 20230321240
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-12
[patent_title] => T CELL RECEPTORS RECOGNIZING R273C OR Y220C MUTATIONS IN P53
[patent_app_type] => utility
[patent_app_number] => 18/024557
[patent_app_country] => US
[patent_app_date] => 2021-09-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18945
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18024557
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/024557 | T CELL RECEPTORS RECOGNIZING R273C OR Y220C MUTATIONS IN P53 | Sep 1, 2021 | Pending |
Array
(
[id] => 18996190
[patent_doc_number] => 11913023
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-02-27
[patent_title] => Modified B cells and methods of use thereof
[patent_app_type] => utility
[patent_app_number] => 17/465759
[patent_app_country] => US
[patent_app_date] => 2021-09-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 18
[patent_figures_cnt] => 34
[patent_no_of_words] => 28906
[patent_no_of_claims] => 32
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 75
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17465759
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/465759 | Modified B cells and methods of use thereof | Sep 1, 2021 | Issued |
Array
(
[id] => 17299954
[patent_doc_number] => 20210395793
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-23
[patent_title] => USE OF MONENSIN TO REGULATE GLYCOSYLATION OF RECOMBINANT PROTEINS
[patent_app_type] => utility
[patent_app_number] => 17/464115
[patent_app_country] => US
[patent_app_date] => 2021-09-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17472
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17464115
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/464115 | Use of monensin to regulate glycosylation of recombinant proteins | Aug 31, 2021 | Issued |
Array
(
[id] => 17996685
[patent_doc_number] => 11497771
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-11-15
[patent_title] => Plasmid combination and application thereof in preparing modified immune cells
[patent_app_type] => utility
[patent_app_number] => 17/412617
[patent_app_country] => US
[patent_app_date] => 2021-08-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 17
[patent_no_of_words] => 15108
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 63
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17412617
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/412617 | Plasmid combination and application thereof in preparing modified immune cells | Aug 25, 2021 | Issued |
Array
(
[id] => 18656244
[patent_doc_number] => 20230302133
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-28
[patent_title] => TARGETED PROTEIN DEGRADATION IN THERAPEUTIC CELLS
[patent_app_type] => utility
[patent_app_number] => 18/020611
[patent_app_country] => US
[patent_app_date] => 2021-08-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17725
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18020611
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/020611 | TARGETED PROTEIN DEGRADATION IN THERAPEUTIC CELLS | Aug 23, 2021 | Pending |
Array
(
[id] => 17274743
[patent_doc_number] => 20210380941
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-09
[patent_title] => Growth and Survival Compositions for Cells Capable of Producing Antibodies and Methods Related Thereto
[patent_app_type] => utility
[patent_app_number] => 17/406212
[patent_app_country] => US
[patent_app_date] => 2021-08-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7359
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17406212
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/406212 | Growth and survival compositions for cells capable of producing antibodies and methods related thereto | Aug 18, 2021 | Issued |
Array
(
[id] => 17275868
[patent_doc_number] => 20210382066
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-09
[patent_title] => Methods of Culturing and Characterizing Antibody Secreting Cells
[patent_app_type] => utility
[patent_app_number] => 17/405918
[patent_app_country] => US
[patent_app_date] => 2021-08-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10934
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 87
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17405918
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/405918 | Methods of culturing and characterizing antibody secreting cells | Aug 17, 2021 | Issued |
Array
(
[id] => 18691044
[patent_doc_number] => 20230321237
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-12
[patent_title] => REGULATORY T CELL EPITOPES
[patent_app_type] => utility
[patent_app_number] => 18/040226
[patent_app_country] => US
[patent_app_date] => 2021-08-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 57855
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -73
[patent_words_short_claim] => 49
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18040226
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/040226 | REGULATORY T CELL EPITOPES | Aug 12, 2021 | Pending |
Array
(
[id] => 18691046
[patent_doc_number] => 20230321239
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-12
[patent_title] => CHIMERIC ANTIGEN RECEPTOR T CELLS FOR TREATING AUTOIMMUNITY
[patent_app_type] => utility
[patent_app_number] => 18/041542
[patent_app_country] => US
[patent_app_date] => 2021-08-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34548
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 53
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18041542
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/041542 | CHIMERIC ANTIGEN RECEPTOR T CELLS FOR TREATING AUTOIMMUNITY | Aug 12, 2021 | Pending |
Array
(
[id] => 18420474
[patent_doc_number] => 20230174936
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-08
[patent_title] => IMMUNOSUPPRESSANT-RESISTANT T-CELLS FOR ADOPTIVE IMMUNOTHERAPY
[patent_app_type] => utility
[patent_app_number] => 17/998058
[patent_app_country] => US
[patent_app_date] => 2021-08-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28436
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17998058
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/998058 | IMMUNOSUPPRESSANT-RESISTANT T-CELLS FOR ADOPTIVE IMMUNOTHERAPY | Aug 12, 2021 | Pending |